Trial Profile

A long term safety study of PL-9643

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 15 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PL 9643 (Primary)
Indications Dry eyes
Focus Registrational; Therapeutic Use
Acronyms MELODY-3
Sponsors Palatin Technologies

Most Recent Events

08 May 2025 According to a Palatin Technologies media release, topline data anticipated in the second half of 2026.
29 Apr 2025 According to a Palatin Technologies media release, subject to securing a collaboration and funding, patient enrollment could begin in the second half of this year, with topline data in the second half of next year
13 Feb 2025 According to a Palatin Technologies media release, FDA agreement on sign and symptom endpoints for remaining two Phase 3 pivotal trial protocols, with patient enrollment prepared to commence 1H calendar year 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com